Skip to content
wolf-dieter_ludwig

Affiliation

Helios Clinic Berlin-Buch

Country

Germany

1. Current Status, Position

Chairman of the Dept. of Hematology, Oncology, and Tumor Immunology at the HELIOS Clinic Berlin-Buch/Chairman of the DCGMA.

2. Education

  • 1979-1981: Dept. of Experimental Pharmacology at the Free University of Berlin, FRG
  • 1982: Ph.D. degree in Medicine, Free University of Berlin, FRG
  • 1981-1988: Clinical resident in the Dept. of Hematology and Oncology, University Clinic Steglitz, Free University of Berlin, FRG
  • 1988: Degree for specialisation in Internal Medicine
  • 1989: Degree for specialisation in Transfusion Medicine
  • 1990: Habilitation for Internal Medicine, Free University of Berlin, FRG
  • 1992: Degree for specialisation in Hematology and Oncology
  • December 1993-March 2001: Deputy Medical Director, Dept. of Medical Oncology and Applied Molecular Biology (renamed 1996: Dept. of Hematology, Oncology, and Tumor Immunology), Robert Rössle Clinic, Charité, Campus Berlin-Buch, FRG
  • Since 1994: Full Professor of Hematology/Oncology and Applied Molecular Biology with unlimited tenure, Humboldt University of Berlin
  • Since April 2001: Medical Director and Head of the Dept. of Hematology, Oncology, and Tumor Immunology, Robert Rössle Clinic, HELIOS Klinikum Berlin-Buch, Charité, Campus Berlin-Buch, FRG
  • 1994: Founding member of the "European Group for the Immunological Characterization of Leukemias" (EGIL)
  • Since December 1999: in the board of the Drug Commission of the German Medical Association (DCGMA)
  • 2002-2005: Full member and chairman of the Panel of Experts at the German Ministry of Health dealing with off label use of drugs
  • Since 2004: Expert for risk management at the European Medicines Agency (EMEA); member of the Scientific Advisory Group (SAG)-Oncology
  • Since 2006: Chairman of the Drug Commission of the German Medical Association (DCGMA)

3. Research Area

Prof. Dr. Ludwig focuses his work on the following research areas:

  • Biologic determinants of treatment response in acute leukemias (e.g., expression and function of apoptosis-related regulatory molecules, minimal residual disease); functional genomics both in translational research and model systems of acute leukemia (coordinator of the Acute Leukemia Consortium within the NGFN, National Genome Research Net);
  • Innovative treatment strategies in oncology (e.g., bispecific monoclonal antibodies, targeted therapy);
  • Pharmacovigilance, especially postmarketing surveillance; international harmonization of drug regulation/approvals;
  • Issues of medical ethics and professional norms regarding academic-industry collaboration.
×

Deadline extended to July 15th

Problems caused by shortages are serious, threaten patient care and require urgent action.

Help us provide an overview of the scale of the problem, as well as insights into the impact on overall patient care.

Our aim is to investigate the causes of medicine and medical device shortages in the hospital setting,  while also gathering effective solutions and best practices implemented at local, regional, and national levels.

×

Join us in Prague for the 2nd edition of BOOST!

Secure your spot in the Movement for Shortage-Free World

BOOST is where visionaries, innovators, and healthcare leaders come together to tackle one of the biggest challenges in hospital pharmacy—medicine shortages.